MagnetoElectric and Ultrasonic Technology for Advanced BRAIN modulationbroad
META-BRAIN · Horizon Europe grant · 2024-01-01–2026-12-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-PATHFINDEROPEN-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2023-PATHFINDEROPEN-01-01. CORDIS record →
Objective
The pathological alterations of neurological function (e.g., stroke, trauma, neurodegeneration, epilepsy, neuropsychiatric diseases, chronic pain) are commonly associated with alterations in brain rhythms and activity patterns. There is an urgent clinical need for treatments that can precisely control and restore neural activity, taking advantage of state-of-the-art technological developments in a variety of fields including nanotechnology, nano- and microelectronics, novel materials, brain science, clinical neurology, and computational modelling. META-BRAIN (MagnetoElectric and Ultrasonic Technology for Advanced BRAIN modulation) brings together seven expert partners in these fields with the aim of achieving precise spatiotemporal control of brain activity using magnetoelectric nanoarchitectures that can be polarized by non-invasive, remote magnetic fields. This novel principle of brain activity control will minimize the amplitude of the required magnetic fields, be wireless, and have enhanced spatial resolution from single neurons to cortical areas. We will develop a model-driven fabrication of the coils and monitor the effects on brain function with arrays of graphene microtransistors that uniquely allow full-band recording, integrating all elements in a closed loop. As an alternative to remote brain stimulation we will also use novel ultrasonic technologies. The META-BRAIN control paradigm will be systematically studied in pre-clinical systems from individual neurons to the full brain. All developments and experiments will be carried out in conjunction with theoretical models that will simulate, quantify, and predict optimal arrangements and patterns for the desired output. Translation to humans will be evaluated with our clinical partners, and a detailed dissemination and exploitation plan will be developed by two expert company partners, one of which has extensive expertise in the fabrication of brain interface devices with a worldwide distribution capability.
Beneficiaries (8)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER | ES | coordinator | €953,420 | |
| CONSIGLIO NAZIONALE DELLE RICERCHE | IT | participant | €775,000 | |
| G.TEC MEDICAL ENGINEERING GMBH DFM profile | AT | participant | €771,875 | Yes |
| KYPRIAKO IDRYMA EREVNON GIA TI MYIKI DISTROFIA | CY | participant | €427,500 | |
| CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. | ES | participant | €362,610 | |
| ZABALA INNOVATION CONSULTING SA | ES | participant | €167,500 | |
| HOSPITAL CLINIC DE BARCELONA | ES | thirdParty | €0 | |
| EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH | CH | associatedPartner | — |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.